Cargando…
Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal Hyperplasia
OBJECTIVE: Intimal hyperplasia is associated with graft failure and vascular sutures in the first year after surgery and in postangioplasty restenosis. Allium sativum (common garlic) lowers cholesterol and has antioxidant effects; it also has antiplatelet and antitumor properties and, therefore, has...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Cirurgia Cardiovascular
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094421/ https://www.ncbi.nlm.nih.gov/pubmed/27849301 http://dx.doi.org/10.5935/1678-9741.20160069 |
_version_ | 1782465101239943168 |
---|---|
author | Lima, Paulo Roberto da Silva Bandeira, Francisco Chavier Vieira Rolim, Janio Cipriano Nogueira, Manuel Ricardo Sena Pordeus, Mizael Armando Abrantes de Oliveira, Andressa Feitosa Bezerra Pitta, Guilherme Benjamin Brandão |
author_facet | Lima, Paulo Roberto da Silva Bandeira, Francisco Chavier Vieira Rolim, Janio Cipriano Nogueira, Manuel Ricardo Sena Pordeus, Mizael Armando Abrantes de Oliveira, Andressa Feitosa Bezerra Pitta, Guilherme Benjamin Brandão |
author_sort | Lima, Paulo Roberto da Silva |
collection | PubMed |
description | OBJECTIVE: Intimal hyperplasia is associated with graft failure and vascular sutures in the first year after surgery and in postangioplasty restenosis. Allium sativum (common garlic) lowers cholesterol and has antioxidant effects; it also has antiplatelet and antitumor properties and, therefore, has great potential to reduce or inhibit intimal hyperplasia of the arteries. Our objective is to determine if the garlic has an efficacy to inhibit myointimal hyperplasia compared to cilostazol. METHODS: Female New Zealand rabbits were divided into the following groups (n=10 each) according to treatment: group A, garlic, 800 µg×kg-(1)×day-(1), orally; group C, cilostazol, 50 mg.day-(1), orally; group PS, 10 ml of 0.9% physiological saline solution, orally. Our primary is the difference of the mean of myointimal hyperplasia. Statistical analysis was performed by using ANOVA and Tukey tests, as well as the Chi-square test. We calculated the 95% confidence interval for each point estimate, and the P value was set as < 0.05. RESULTS: Group PS had a mean hyperplasia rate of 35.74% (95% CI, 31.76–39.71%); group C, 16.21% (95% CI, 13.36–19.05%); and group A, 21.12% (95% CI, 17.26–25.01%); P<0.0001. CONCLUSION: We conclude that Allium sativum had the same efficacy in inhibiting myointimal hyperplasia when compared to the positive control, cilostazol. |
format | Online Article Text |
id | pubmed-5094421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Sociedade Brasileira de Cirurgia Cardiovascular |
record_format | MEDLINE/PubMed |
spelling | pubmed-50944212016-11-04 Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal Hyperplasia Lima, Paulo Roberto da Silva Bandeira, Francisco Chavier Vieira Rolim, Janio Cipriano Nogueira, Manuel Ricardo Sena Pordeus, Mizael Armando Abrantes de Oliveira, Andressa Feitosa Bezerra Pitta, Guilherme Benjamin Brandão Braz J Cardiovasc Surg Original Article OBJECTIVE: Intimal hyperplasia is associated with graft failure and vascular sutures in the first year after surgery and in postangioplasty restenosis. Allium sativum (common garlic) lowers cholesterol and has antioxidant effects; it also has antiplatelet and antitumor properties and, therefore, has great potential to reduce or inhibit intimal hyperplasia of the arteries. Our objective is to determine if the garlic has an efficacy to inhibit myointimal hyperplasia compared to cilostazol. METHODS: Female New Zealand rabbits were divided into the following groups (n=10 each) according to treatment: group A, garlic, 800 µg×kg-(1)×day-(1), orally; group C, cilostazol, 50 mg.day-(1), orally; group PS, 10 ml of 0.9% physiological saline solution, orally. Our primary is the difference of the mean of myointimal hyperplasia. Statistical analysis was performed by using ANOVA and Tukey tests, as well as the Chi-square test. We calculated the 95% confidence interval for each point estimate, and the P value was set as < 0.05. RESULTS: Group PS had a mean hyperplasia rate of 35.74% (95% CI, 31.76–39.71%); group C, 16.21% (95% CI, 13.36–19.05%); and group A, 21.12% (95% CI, 17.26–25.01%); P<0.0001. CONCLUSION: We conclude that Allium sativum had the same efficacy in inhibiting myointimal hyperplasia when compared to the positive control, cilostazol. Sociedade Brasileira de Cirurgia Cardiovascular 2016 /pmc/articles/PMC5094421/ /pubmed/27849301 http://dx.doi.org/10.5935/1678-9741.20160069 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lima, Paulo Roberto da Silva Bandeira, Francisco Chavier Vieira Rolim, Janio Cipriano Nogueira, Manuel Ricardo Sena Pordeus, Mizael Armando Abrantes de Oliveira, Andressa Feitosa Bezerra Pitta, Guilherme Benjamin Brandão Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal Hyperplasia |
title | Allium sativum Compared to Cilostazol as an Inhibitor of
Myointimal Hyperplasia |
title_full | Allium sativum Compared to Cilostazol as an Inhibitor of
Myointimal Hyperplasia |
title_fullStr | Allium sativum Compared to Cilostazol as an Inhibitor of
Myointimal Hyperplasia |
title_full_unstemmed | Allium sativum Compared to Cilostazol as an Inhibitor of
Myointimal Hyperplasia |
title_short | Allium sativum Compared to Cilostazol as an Inhibitor of
Myointimal Hyperplasia |
title_sort | allium sativum compared to cilostazol as an inhibitor of
myointimal hyperplasia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094421/ https://www.ncbi.nlm.nih.gov/pubmed/27849301 http://dx.doi.org/10.5935/1678-9741.20160069 |
work_keys_str_mv | AT limapaulorobertodasilva alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia AT bandeirafranciscochaviervieira alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia AT rolimjaniocipriano alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia AT nogueiramanuelricardosena alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia AT pordeusmizaelarmandoabrantes alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia AT deoliveiraandressafeitosabezerra alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia AT pittaguilhermebenjaminbrandao alliumsativumcomparedtocilostazolasaninhibitorofmyointimalhyperplasia |